# Octreotide (Sandostatin)

> Synthetic somatostatin analog for acromegaly and neuroendocrine tumors.

Source: https://peptides.cafe/peptide/octreotide
Category: Somatostatin Analog · Oncology
Tag: FDA-Approved · Endocrine

## Mechanism
An 8-amino-acid synthetic analog of somatostatin that binds somatostatin receptors (primarily SSTR2 and SSTR5), suppressing growth hormone, glucagon, insulin, and several gastrointestinal hormones. Longer half-life than native somatostatin enables therapeutic use.

## Research areas
- Acromegaly
- Carcinoid syndrome
- VIPomas
- Variceal bleeding
- Neuroendocrine tumors

## Common research protocols
- Acromegaly: Subcutaneous 50–200 mcg 3×/day, or long-acting depot (LAR) monthly IM.
- Carcinoid syndrome: Depot LAR 20–30 mg IM every 4 weeks.

## Study summaries
- "Octreotide LAR in acromegaly" — NEJM (2000): Pivotal trial demonstrating normalization of GH and IGF-1 with monthly depot dosing.

## Considerations
- FDA-approved.
- Gallstones, hyperglycemia, GI upset are common adverse effects.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.